| |
Record participation at 2012 Advanced Technologies and Treatments for Diabetes Conference
The Advanced Technologies and Treatments for Diabetes Conference, which was held earlier this month in Barcelona counted this year a record number of attendees. Launched in 2008 with over 700 participants, in its fifth year almost 1700 experts visited the conference.
The ATTD conference is known throughout the medical world as the vanguard industry event to convene and actively work together to present innovative solutions for better treatment. By offering a platform for the launch of new and diverse medical practices and devices, the organizers aim to significantly contribute to the knowledge of diabetes treatment and prevention of related illnesses that can lead to it. The ATTD conference is chaired by Professor Moshe Philip and Professor Tadej Battelino, experts in the field of diabetes treatment.
Professionals from Europe (56%), North America (13%) and other parts of the world took part and contributed to 22 sessions on a variety of crucial topics related to treatment and prevention of diabetes and other causes that can lead to this malicious disease.
ATTD was attended by key industry leaders from the field of endocrinology, biotechnology, pediatrics and others. It was sponsored by internationally renowned medical enterprises such as Roche, Medtronic, Animas (Johnson & Johnson) and others.
Starting today industry experts will be gathering in Barcelona to race against these statistics and challenges. With governments allotting an average 5-10% of the national budget to treat diabetes, one of the major causes of premature illness and death worldwide, industry experts from all over the world will be discussing technological solutions to curb this disease.
About ATTD
Launched in 2008 in Prague, Czech Republic, ATTD is an innovative diabetes technologies and treatments conference for researchers, clinicians and general practitioners in all fields of diabetes, endocrinology and metabolism and is yearly sponsored by key medical leaders. With over 1,500 participants and first class key note speakers in the field, the conference is considered the go-to networking event for researchers, clinicians and general practitioners in all fields of diabetes, endocrinology and metabolism. For the first time in 2012 the conference featured new and innovative technologies and medical devices for diabetes treatment by start-ups and new emerging companies.
|
rebecca[.]bottoml.com 
